Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VZ9S
|
|||
| Former ID |
DIB004471
|
|||
| Drug Name |
CROMOGLYCATE LISETIL HYDROCHLORIDE
|
|||
| Synonyms |
Diethyl L-lysylcromoglycate dihydrochloride; KY-556; N-556; Cromoglycate lisetil hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H36N2O12
|
|||
| Canonical SMILES |
CCOC(=O)C1=CC(=O)C2=C(O1)C=CC=C2OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)OCC)OC(=O)C(CCCCN)N
|
|||
| InChI |
1S/C33H36N2O12/c1-3-41-32(39)27-15-21(36)29-23(10-7-12-25(29)46-27)43-17-19(45-31(38)20(35)9-5-6-14-34)18-44-24-11-8-13-26-30(24)22(37)16-28(47-26)33(40)42-4-2/h7-8,10-13,15-16,19-20H,3-6,9,14,17-18,34-35H2,1-2H3/t20-/m0/s1
|
|||
| InChIKey |
NGJJDHCBOKNREV-FQEVSTJZSA-N
|
|||
| CAS Number |
CAS 110816-79-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:31438
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium-activated potassium channel KCa1.1 (KCNMA1) | Target Info | Modulator | [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Vascular smooth muscle contraction | ||||
| Insulin secretion | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Reactome | cGMP effects | |||
| WikiPathways | Potassium Channels | |||
| Platelet homeostasis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01722812) Cromoglicate in Psoriasis. U.S. National Institutes of Health. | |||
| REF 2 | The significance of chloride in the inhibitory action of disodium cromoglycate on immunologically-stimulated rat peritoneal mast cells. Biochim Biophys Acta. 2011 Sep;1810(9):867-74. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.